{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:43:44Z","timestamp":1793378624660,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2023YFC3605702"],"award-info":[{"award-number":["2023YFC3605702"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773767"],"award-info":[{"award-number":["81773767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bcp.2024.116731","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T23:57:54Z","timestamp":1734652674000},"page":"116731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel"],"prefix":"10.1016","volume":"232","author":[{"given":"Fenglan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9875-5721","authenticated-orcid":false,"given":"Wenfu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2024.116731_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2024.116731_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116731_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112446","article-title":"Single and dual target inhibitors based on Bcl-2: promising anti-tumor agents for cancer therapy","volume":"201","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2024.116731_b0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/med.21999","article-title":"B-cell lymphoma-2 family proteins in the crosshairs: small molecule inhibitors and activators for cancer therapy","volume":"44","author":"Gong","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2024.116731_b0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2024.116731_b0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: first global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2024.116731_b0035","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2024.116731_b0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116731_b0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116731_b0050","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2024.116731_b0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"Pt 2","key":"10.1016\/j.bcp.2024.116731_b0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: a novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116731_b0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116731_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2164-14-1","article-title":"The complex transcriptional landscape of the anucleate human platelet","volume":"14","author":"Bray","year":"2013","journal-title":"BMC Genomics"},{"issue":"12","key":"10.1016\/j.bcp.2024.116731_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081809","article-title":"Next generation sequencing analysis of human platelet PolyA+ mRNAs and rRNA-depleted total RNA","volume":"8","author":"Kissopoulou","year":"2013","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.bcp.2024.116731_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bcp.2024.116731_b0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Nieto-Jim\u00e9nez","year":"2022","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2024.116731_b0090","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.7150\/thno.75421","article-title":"The PROTAC selectively degrading Bcl-x(L) represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bcp.2024.116731_b0095","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL","volume":"36","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2024.116731_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111826","article-title":"BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis","volume":"41","author":"Bharti","year":"2022","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bcp.2024.116731_b0105","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1078-0432.CCR-10-2353","article-title":"Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models","volume":"17","author":"Tan","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"279","key":"10.1016\/j.bcp.2024.116731_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.bcp.2024.116731_b0115","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev."},{"issue":"279","key":"10.1016\/j.bcp.2024.116731_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bcp.2024.116731_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065657","article-title":"BCL-XL overexpression protects pancreatic \u03b2-cells against cytokine- and palmitate-induced apoptosis","volume":"24","author":"Perez-Serna","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.bcp.2024.116731_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214474","article-title":"Bcl-2 Family members Bcl-xL and bax cooperatively contribute to bortezomib resistance in mantle cell lymphoma","volume":"23","author":"Luanpitpong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2024.116731_b0135","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"issue":"17","key":"10.1016\/j.bcp.2024.116731_b0140","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.7150\/thno.75421","article-title":"The PROTAC selectively degrading Bcl-XL represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.bcp.2024.116731_b0145","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ncb3616","article-title":"Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFUtumour suppressor","volume":"19","author":"Wu","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"23","key":"10.1016\/j.bcp.2024.116731_b0150","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1158\/0008-5472.CAN-17-1463","article-title":"Astrocytes promote medulloblastoma progression through hedgehog secretion","volume":"77","author":"Liu","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2024.116731_b0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2004.08.019","article-title":"Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+\/-)p53(-\/-) mice","volume":"6","author":"Romer","year":"2004","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bcp.2024.116731_b0160","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bcp.2024.116731_b0165","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2024.116731_b0170","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL\u2013inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"98","key":"10.1016\/j.bcp.2024.116731_b0175","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1039\/C9CC07217A","article-title":"Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X(L)","volume":"55","author":"Zhang","year":"2019","journal-title":"Chem. Commun. (Camb)"},{"key":"10.1016\/j.bcp.2024.116731_b0180","doi-asserted-by":"crossref","unstructured":"M. Puglisi, L. van Doorn, M. Blanco, M.J. de Jonge, K. Moran, J. Yang, T.A. Busman, C.A. Franklin, M.H. Mabry, A.P. Krivoshik, A phase I safety and pharmacokinetic (PK) study of navitoclax in combination with docetaxel in patients with solid tumors, (2011).","DOI":"10.1200\/jco.2011.29.15_suppl.2518"},{"issue":"5","key":"10.1016\/j.bcp.2024.116731_b0185","article-title":"It's time to die: BH3 mimetics in solid tumors","volume":"1868","author":"Kehr","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.bcp.2024.116731_b0190","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 Is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bcp.2024.116731_b0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41419-020-02760-y","article-title":"Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options","volume":"11","author":"Wu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2024.116731_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice","volume":"9","author":"Khan","year":"2023","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.bcp.2024.116731_b0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13104-018-3302-0","article-title":"Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines","volume":"11","author":"Lian","year":"2018","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.bcp.2024.116731_b0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.041","article-title":"Targeting BCL-2 proteins in pediatric cancer: dual inhibition of BCL-X(L) and MCL-1 leads to rapid induction of intrinsic apoptosis","volume":"482","author":"Kehr","year":"2020","journal-title":"Cancer Lett."},{"issue":"32","key":"10.1016\/j.bcp.2024.116731_b0215","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"issue":"7336","key":"10.1016\/j.bcp.2024.116731_b0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2024.116731_b0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bcp.2011.10.008","article-title":"Cdk1\/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration","volume":"83","author":"Chu","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116731_b0230","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2024.116731_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113546","article-title":"NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes","volume":"154","author":"Daressy","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116731_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224007329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224007329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:12:11Z","timestamp":1738818731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224007329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"alternative-id":["S0006295224007329"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116731","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116731"}}